Canurta Therapeutics

Canurta Therapeutics is a biotech company that has developed a proprietary platform that can produce high-purity botanical compounds for neurodegenerative disease treatments, particularly ALS. Current treatments for ALS often target only a single pathway, leaving patients with limited solutions. Canurta’s CNR 401, derived from rare botanical sources like cannflavins, provides a more comprehensive multi-pathway treatment. The venture’s ML-powered platform enables the efficient extraction, design, and testing of these rare molecules. Canurta leverages cutting-edge research from the University of Guelph and is backed by a team with proven success in bringing botanical drugs to market, which will help position the company well for regulatory approval and market traction.